98 related articles for article (PubMed ID: 23420665)
1. Structural investigation of the VEGF receptor interaction with a helical antagonist peptide.
Diana D; Di Stasi R; De Rosa L; Isernia C; D'Andrea LD; Fattorusso R
J Pept Sci; 2013 Apr; 19(4):214-9. PubMed ID: 23420665
[TBL] [Abstract][Full Text] [Related]
2. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
3. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
Bae DG; Kim TD; Li G; Yoon WH; Chae CB
Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding.
Iyer S; Scotney PD; Nash AD; Ravi Acharya K
J Mol Biol; 2006 May; 359(1):76-85. PubMed ID: 16616187
[TBL] [Abstract][Full Text] [Related]
5. Development of a highly-potent anti-angiogenic VEGF8-109 heterodimer by directed blocking of its VEGFR-2 binding site.
Ghavamipour F; Shahangian SS; Sajedi RH; Arab SS; Mansouri K; Aghamaali MR
FEBS J; 2014 Oct; 281(19):4479-94. PubMed ID: 25132001
[TBL] [Abstract][Full Text] [Related]
6. VEGFR1(D2) in drug discovery: Expression and molecular characterization.
Di Stasi R; Diana D; Capasso D; Palumbo R; Romanelli A; Pedone C; Fattorusso R; D'Andrea LD
Biopolymers; 2010; 94(6):800-9. PubMed ID: 20564033
[TBL] [Abstract][Full Text] [Related]
7. Membrane fixation of vascular endothelial growth factor receptor 1 ligand-binding domain is important for vasculogenesis and angiogenesis in mice.
Hiratsuka S; Nakao K; Nakamura K; Katsuki M; Maru Y; Shibuya M
Mol Cell Biol; 2005 Jan; 25(1):346-54. PubMed ID: 15601855
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a designed vascular endothelial growth factor receptor antagonist helical peptide with antiangiogenic activity in vivo.
Basile A; Del Gatto A; Diana D; Di Stasi R; Falco A; Festa M; Rosati A; Barbieri A; Franco R; Arra C; Pedone C; Fattorusso R; Turco MC; D'Andrea LD
J Med Chem; 2011 Mar; 54(5):1391-400. PubMed ID: 21280635
[TBL] [Abstract][Full Text] [Related]
9. C-terminal truncation of Vascular Endothelial Growth Factor mimetic helical peptide preserves structural and receptor binding properties.
Ziaco B; Diana D; Capasso D; Palumbo R; Celentano V; Di Stasi R; Fattorusso R; D'Andrea LD
Biochem Biophys Res Commun; 2012 Jul; 424(2):290-4. PubMed ID: 22749999
[TBL] [Abstract][Full Text] [Related]
10. Investigating the differential activation of vascular endothelial growth factor (VEGF) receptors.
Horta BA; Sodero AC; de Alencastro RB
J Mol Graph Model; 2009 Oct; 28(3):287-96. PubMed ID: 19734078
[TBL] [Abstract][Full Text] [Related]
11. Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.
Farzaneh Behelgardi M; Zahri S; Gholami Shahvir Z; Mashayekhi F; Mirzanejad L; Asghari SM
Mol Biol Rep; 2020 Mar; 47(3):2061-2071. PubMed ID: 32072404
[TBL] [Abstract][Full Text] [Related]
12. Coordinate expression of vascular endothelial growth factor receptor-1 (flt-1) and its ligand suggests a paracrine regulation of murine vascular development.
Breier G; Clauss M; Risau W
Dev Dyn; 1995 Nov; 204(3):228-39. PubMed ID: 8573716
[TBL] [Abstract][Full Text] [Related]
13. Total chemical synthesis of the D2 domain of human VEGF receptor 1.
Goncalves V; Gautier B; Huguenot F; Leproux P; Garbay C; Vidal M; Inguimbert N
J Pept Sci; 2009 Jun; 15(6):417-22. PubMed ID: 19387974
[TBL] [Abstract][Full Text] [Related]
14. VEGF receptor protein-tyrosine kinases: structure and regulation.
Roskoski R
Biochem Biophys Res Commun; 2008 Oct; 375(3):287-91. PubMed ID: 18680722
[TBL] [Abstract][Full Text] [Related]
15. Peptides encoded by exon 6 of VEGF inhibit endothelial cell biological responses and angiogenesis induced by VEGF.
Jia H; Jezequel S; Löhr M; Shaikh S; Davis D; Soker S; Selwood D; Zachary I
Biochem Biophys Res Commun; 2001 Apr; 283(1):164-73. PubMed ID: 11322784
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
17. Rational design, structure, and biological evaluation of cyclic peptides mimicking the vascular endothelial growth factor.
Goncalves V; Gautier B; Coric P; Bouaziz S; Lenoir C; Garbay C; Vidal M; Inguimbert N
J Med Chem; 2007 Oct; 50(21):5135-46. PubMed ID: 17900101
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. Fluorescent resonance energy transfer imaging of VEGFR dimerization.
Ahmadova Z; Yagublu V; Förg T; Hajiyeva Y; Jesenofsky R; Hafner M; Keese M
Anticancer Res; 2014 May; 34(5):2123-33. PubMed ID: 24778014
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
